
|Videos|October 7, 2014
Ceritinib For Lung Cancer Treatment
Author(s)Quincy Chu, MD
Quincy Chu, MD, associate professor, medical oncologist, University of Alberta, discusses the development of ceritinib.
Advertisement
Quincy Chu, MD, associate professor, medical oncologist, University of Alberta, discusses the development of ceritinib.
Clinical Pearls:
- Ceritinib is a second-generation ALK inhibitor
- In a preclinical setting, ceritinib was found to have activity to the ALK-amplified cell lines as well as in human samples
- Unlike crizotinib, ceritinib does have substantial CNS penetration ​
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































